Aktuelles

Meldungen

NUB-Anträge 2017/8 verfügbar

Die aktuellen Template für die NUB-Anträge 2017/8 sind online.

Weiterlesen …

Präsentation der Studiensitzung verfügbar

Unter untenstehendem Link sind die Präsentationen im Rahmen der Studiensitzung auf dem diesjährigen Hautkrebskongress verfügbar.

Weiterlesen …

Hautkrebskongress 2017: Neue Erkenntnisse und aktuelle Therapiemöglichkeiten in der Dermato-Onkologie

Beim 27. Deutschen Hautkrebskongress der ADO und der Deutschen Dermatologischen Gesellschaft, der vom 21. - 23. September 2017 in Mainz stattfindet, werden vielversprechende aktuelle Erkenntnisse und Forschungsergebnisse in Prävention, Diagnostik und Therapie in der Dermato-Onkologie vorgestellt und von internationalen Experten diskutiert.

Nicht nur in der Therapie des fortgeschrittenen Melanoms, des Basalzellkarzinoms und in der Behandlung aktinischer Keratosen, auch bei anderen Hautkrebsarten gibt es hoffnungsvolle Fortschritte. Herr Prof. Stephan Grabbe und Frau PD Dr. med. Carmen Loquai geben Einblick in Highlights des Kongresses.

Weiterlesen …

Nationale Versorgungskonferenz Hautkrebs verabschiedet Ziele zur besseren Patientenversorgung bis 2021

Die Nationale Versorgungskonferenz Hautkrebs (NVKH) hat ihre Versorgungsziele 2017-2021 verabschiedet. Gemeinsam mit Patientenvertretern haben die beteiligten Fachgesellschaften und Verbände fünf nationale Versorgungsziele gegen den Hautkrebs definiert. Übergeordnetes Ziel ist es, die Prävention und Versorgung von Hautkrebs bundesweit zu verbessern.

Weiterlesen …

Methadon in der Krebstherapie

Seit April 2017 wurde in verschiedenen Medien über den Einsatz von Methadon bei Krebspatienten berichtet. Die Reaktionen sind enorm. Viele Patienten und ihre Angehörigen erkundigen sich nach den Möglichkeiten einer Methadontherapie. Die Deutsche Gesellschaft für Hämatologie und medizinische Onkologie (DGHO) hat nun eine Information für Patienten veröffentlicht. en.

Weiterlesen …

PubMed – Neue Publikationen

Recruiting former melanoma patients via hospitals in comparison to office-based dermatologists in a register-based cohort study that required indirect contact.

Recruiting former melanoma patients via hospitals in comparison to office-based dermatologists in a register-based cohort study that required indirect contact.

BMC Med Res Methodol. 2017 Nov 22;17(1):150

Authors: Zeissig SR, Weyer-Elberich V, Emrich K, Binder H, Fischbeck S, Imruck BH, Friedrich-Mai P, Beutel ME, Blettner M

Abstract
BACKGROUND: There are detailed reviews about different recruitment strategies, but not with regard to differences between recruitment of hospital-based versus office-based physicians. Within this study, the two different recruitment schemes are compared. Advantages and disadvantages of different ways of recruitment in registry-based studies are discussed.
METHODS: In a cross-sectional cancer-registry-based study, long-term melanoma patients were contacted by dermatologists rather than directly by the registry on the basis of the legal situation. Logistic regression models and generalized estimating equations were used to assess effects of various patient and physician characteristics on participation and data quality. Especially differences between hospital-based versus office-based dermatologists are evaluated.
RESULTS: Seventy two out of 112 contacted dermatologists took part in the study (64.3%). The cooperation proportion was 52.2% (689 participants/1320 contacted patients). Participants and non-participants differed regarding age and sex, but not regarding other social demographic factors and cancer stage. We did not observe a difference in patient participation between hospital-based versus office-based dermatologists (OR 1.08 [CI 0.84-1.39]; p = 0.57). However, medical data provided by the cancer registry were better for participants registered and recruited by hospitals.
CONCLUSIONS: In cohort studies with epidemiological cancer registries, recruitment via physicians has potential disadvantages and is more complex. If this indirect way of contact is mandatory, we recommend recruitment procedures including hospital-based rather than office-based physicians. However, physician characteristics were not associated with outcome.

PMID: 29166870 [PubMed - in process]

Synergistic inhibition of cell proliferation by combined targeting with kinase inhibitors and dietary xanthone is a promising strategy for melanoma treatment.

Synergistic inhibition of cell proliferation by combined targeting with kinase inhibitors and dietary xanthone is a promising strategy for melanoma treatment.

Clin Exp Dermatol. 2017 Nov 22;:

Authors: Xia Y, Sun J

Abstract
α-Mangostin is a dietary xanthone that displays various biological activities, and numerous reports have shown its efficacy in cancer prevention and inhibition. As most agents have been shown to be ineffective as single-agent therapy for malignant melanoma (MM), the principle of targeted chemotherapy for MM is to use effective inhibitors and combination methods. In this study, we tested the cytotoxicity of several kinase inhibitors, including the glycogen synthase kinase (GSK)-3 inhibitor CHIR99021, and rapamycin, in combination with a dietary xanthone, α-mangostin, by screening from a kinase inhibitor library for melanogenesis in SK-MEL-2 MM cells, and verified these by clone formation efficiency, terminal dUTP nick end labelling, and expression of apoptosis-related proteins. We also explored the molecular mechanisms for the apoptosis-inducing effects reported. We found a marked synergistic effect of CHIR99021 or rapamycin in combination with α-mangostin, which we verified through apoptosis-related methods. These data provide a strong rationale for the use of α-mangostin as an adjunct to GSK-3 inhibitor or mammalian target of rapamycin inhibitor treatment. The intrinsic mechanism behind α-mangostin might be inhibition of phosphatidylinositol 3-kinase/AKT signalling and autophagy, and induction of reactive oxygen species generation.

PMID: 29168273 [PubMed - as supplied by publisher]

Sampling of Wide Local Excision Specimens in Cutaneous Malignant Melanoma.

Sampling of Wide Local Excision Specimens in Cutaneous Malignant Melanoma.

J Cutan Pathol. 2017 Nov 23;:

Authors: Fives C, Heffron CCBB

Abstract
BACKGROUND: Wide local excisions (WLE) are frequently undertaken in the management of cutaneous melanoma; however there is considerable variability in their macroscopic sampling. The aim of our study was to establish evidence-based guidelines for the macroscopic handling of these specimens with a subsequent review of the impact on our service.
METHODS: The study group of 128 cases with initial biopsy and subsequent WLE in our institution in 2010 were identified by a computer-generated search. From analysis of this group, guidelines for macroscopic sampling were derived with a repeat search performed in 2012.
RESULTS: Residual melanoma was detected only in those cases in which the original specimen had clear margins of ≤1mm or with a pigmented lesion. A 32% increase in case numbers was noted over this period with a reduction of 6.2% in block numbers. Average block numbers per case were reduced by 2.3 (30.7%).
CONCLUSIONS: We have shown that for WLE specimens with no evidence of a macroscopic lesion and clear margins on original biopsy, little is to be gained from extensive sampling. In these cases we recommend a maximum of 3 blocks per case. Reduction in sampling based on this evidence would result in saving valuable laboratory resources.

PMID: 29168591 [PubMed - as supplied by publisher]

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.

Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.

Rom J Intern Med. 2017 Nov 27;:

Authors: Popescu A, Haidar A, Anghel RM

Abstract
Recent years have brought major advances in the treatment of malignant melanoma. One such an advance is the treatment with BRAF tyrosine-kinase inhibitors in metastatic malignant melanomas that harbor mutations in the BRAF gene. The trials that have been performed in this setting have demonstrated superior response rates and increased overall survival, however they mostly included patients with melanomas carrying the more common V600E and V600K mutations, not being able to assess the benefit of these treatments in situations where more rare mutations of the BRAF gene are present. We present the evolution of a patient with malignant melanoma with a rare V600M mutation in the BRAF gene, that was eventually treated with vemurafenib. Also we present a brief review of the major phase III trials that showed benefit with tyrosine-kinase inhibitors in BRAF mutated melanoma, with respect to the BRAF mutations included.

PMID: 29168975 [PubMed - as supplied by publisher]

Three year Experience of Non-Melanoma Skin Cancer in a General Practice.

Three year Experience of Non-Melanoma Skin Cancer in a General Practice.

Ir Med J. 2017 Aug 12;110(7):616

Authors: Maguire J, Maguire N

Abstract
We report 85 lesions of non-melanoma skin cancer in 58 patients, representing 9% of the minor surgical workload of a single general practitioner. Cases were studied in order to describe pathology, management and outcomes. Eighteen percent of lesions were referred, mainly because of central facial site and larger size. Of the lesions treated in the surgery, all but four were treated surgically. Quantitative margins of lateral and deep excision were reported for 50% and 30% of specimens respectively. Lateral histological margins of clearance were narrower for head and neck lesions. Incomplete excision occurred in 4%. There was one recurrent lesion after two years of follow-up. A majority of non-melanoma skin cancers at this clinic were managed safely without referral to secondary care. Quantitative reporting of tumour free margins for skin cancer is lacking.

PMID: 29168998 [PubMed - in process]

ADO | Geschäftsstelle • Science Park 2 • 66123 Saarbrücken • Tel. 0681 9358 6604 • E-Mail: geschaeftsstelle@ado-homepage.de
ADO | Leitliniensekretariat • Science Park 2 • 66123 Saarbrücken • Tel. 0681 9358 4218 [Mo.-Do.: 9-14h] • E-Mail: info@hautkrebs-leitlinien.de

Die ADO-Website nutzt zur Bereitstellung ihrer Dienste Cookies. Sollten Sie damit nicht einverstanden sein, können Sie Cookies in Ihren Browser-Einstellungen deaktivieren.